Compromised LCAT Function Is Associated With Increased Atherosclerosis | Zendy

G. Kees Hovingh | Zendy; Barbara A. Hutten | Zendy; Adriaan G. Holleboom | Zendy; Wilma Petersen | Zendy; Patrick Rol | Zendy; Anton F. H. Stalenhoef | Zendy; Aeilko H. Zwinderman | Zendy; Eric de Groot | Zendy; John J.P. Kastelein | Zendy; Jan Albert Kuivenhoven | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Compromised LCAT Function Is Associated With Increased Atherosclerosis

Author(s) -

G. Kees Hovingh,

Barbara A. Hutten,

Adriaan G. Holleboom,

Wilma Petersen,

Patrick Rol,

Anton F. H. Stalenhoef,

Aeilko H. Zwinderman,

Eric de Groot,

John J.P. Kastelein,

Jan Albert Kuivenhoven

Publication year - 2005

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.540427

Subject(s) - medicine , endocrinology , heterozygote advantage , cholesterol , triglyceride , apolipoprotein b , lecithin—cholesterol acyltransferase , lecithin , sterol o acyltransferase , lipoprotein , allele , gene , biology , genetics , biochemistry

Prospective epidemiological studies have shown that low plasma levels of HDL cholesterol (HDL-C) are associated with an increased risk for cardiovascular disease (CVD). Despite nearly 40 years of research, however, it is unclear whether this also holds true for individuals with severely reduced levels of HDL-C due to mutations in the lecithin:cholesterol acyltransferase (LCAT) gene. Better insight into CVD risk in these individuals may provide clues toward the potential of LCAT as a pharmaceutical target to raise HDL-C levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research